List of Tables
Table 1. Oncology Immunotherapy Market Trends
Table 2. Oncology Immunotherapy Market Drivers & Opportunity
Table 3. Oncology Immunotherapy Market Challenges
Table 4. Oncology Immunotherapy Market Restraints
Table 5. Global Oncology Immunotherapy Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Oncology Immunotherapy Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Oncology Immunotherapy Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Oncology Immunotherapy Product Type
Table 9. Key Companies Time to Begin Mass Production of Oncology Immunotherapy
Table 10. Global Oncology Immunotherapy Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Immunotherapy as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Oncology Immunotherapy Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Oncology Immunotherapy Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Oncology Immunotherapy Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Oncology Immunotherapy Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Oncology Immunotherapy Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Oncology Immunotherapy Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Oncology Immunotherapy Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Oncology Immunotherapy Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Oncology Immunotherapy Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Oncology Immunotherapy Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Oncology Immunotherapy Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Oncology Immunotherapy Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Oncology Immunotherapy Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Oncology Immunotherapy Sales Value by Region (2019-2024) & (%)
Table 27. Global Oncology Immunotherapy Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Oncology Immunotherapy Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Oncology Immunotherapy Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Oncology Immunotherapy Sales Value, (2025-2030) & (US$ Million)
Table 31. Bristol-Myers Squibb Basic Information List
Table 32. Bristol-Myers Squibb Description and Business Overview
Table 33. Bristol-Myers Squibb Oncology Immunotherapy Products, Services and Solutions
Table 34. Revenue (US$ Million) in Oncology Immunotherapy Business of Bristol-Myers Squibb (2019-2024)
Table 35. Bristol-Myers Squibb Recent Developments
Table 36. Merck & Co Basic Information List
Table 37. Merck & Co Description and Business Overview
Table 38. Merck & Co Oncology Immunotherapy Products, Services and Solutions
Table 39. Revenue (US$ Million) in Oncology Immunotherapy Business of Merck & Co (2019-2024)
Table 40. Merck & Co Recent Developments
Table 41. Roche AG Basic Information List
Table 42. Roche AG Description and Business Overview
Table 43. Roche AG Oncology Immunotherapy Products, Services and Solutions
Table 44. Revenue (US$ Million) in Oncology Immunotherapy Business of Roche AG (2019-2024)
Table 45. Roche AG Recent Developments
Table 46. AstraZeneca Basic Information List
Table 47. AstraZeneca Description and Business Overview
Table 48. AstraZeneca Oncology Immunotherapy Products, Services and Solutions
Table 49. Revenue (US$ Million) in Oncology Immunotherapy Business of AstraZeneca (2019-2024)
Table 50. AstraZeneca Recent Developments
Table 51. Sanofi S.A. Basic Information List
Table 52. Sanofi S.A. Description and Business Overview
Table 53. Sanofi S.A. Oncology Immunotherapy Products, Services and Solutions
Table 54. Revenue (US$ Million) in Oncology Immunotherapy Business of Sanofi S.A. (2019-2024)
Table 55. Sanofi S.A. Recent Developments
Table 56. Dendreon Pharmaceuticals Basic Information List
Table 57. Dendreon Pharmaceuticals Description and Business Overview
Table 58. Dendreon Pharmaceuticals Oncology Immunotherapy Products, Services and Solutions
Table 59. Revenue (US$ Million) in Oncology Immunotherapy Business of Dendreon Pharmaceuticals (2019-2024)
Table 60. Dendreon Pharmaceuticals Recent Developments
Table 61. Novartis Basic Information List
Table 62. Novartis Description and Business Overview
Table 63. Novartis Oncology Immunotherapy Products, Services and Solutions
Table 64. Revenue (US$ Million) in Oncology Immunotherapy Business of Novartis (2019-2024)
Table 65. Novartis Recent Developments
Table 66. Gilead Sciences Inc. Basic Information List
Table 67. Gilead Sciences Inc. Description and Business Overview
Table 68. Gilead Sciences Inc. Oncology Immunotherapy Products, Services and Solutions
Table 69. Revenue (US$ Million) in Oncology Immunotherapy Business of Gilead Sciences Inc. (2019-2024)
Table 70. Gilead Sciences Inc. Recent Developments
Table 71. Merck KGaA Basic Information List
Table 72. Merck KGaA Description and Business Overview
Table 73. Merck KGaA Oncology Immunotherapy Products, Services and Solutions
Table 74. Revenue (US$ Million) in Oncology Immunotherapy Business of Merck KGaA (2019-2024)
Table 75. Merck KGaA Recent Developments
Table 76. Key Raw Materials Lists
Table 77. Raw Materials Key Suppliers Lists
Table 78. Oncology Immunotherapy Downstream Customers
Table 79. Oncology Immunotherapy Distributors List
Table 80. Research Programs/Design for This Report
Table 81. Key Data Information from Secondary Sources
Table 82. Key Data Information from Primary Sources
Table 83. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Oncology Immunotherapy Product Picture
Figure 2. Global Oncology Immunotherapy Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Oncology Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 4. Oncology Immunotherapy Report Years Considered
Figure 5. Global Oncology Immunotherapy Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Oncology Immunotherapy Revenue in 2023
Figure 7. Oncology Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Immune Checkpoint Inhibitors Picture
Figure 9. Cytokine-Based Immunotherapy Picture
Figure 10. Cancer Vaccines Picture
Figure 11. CAR-T Cell Therapy Picture
Figure 12. Other Picture
Figure 13. Global Oncology Immunotherapy Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Oncology Immunotherapy Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Hospitals
Figure 16. Product Picture of Drugstores
Figure 17. Product Picture of Others
Figure 18. Global Oncology Immunotherapy Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Oncology Immunotherapy Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Oncology Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Oncology Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Oncology Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Oncology Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Oncology Immunotherapy Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Oncology Immunotherapy Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Oncology Immunotherapy Sales Value (%), (2019-2030)
Figure 31. United States Oncology Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Oncology Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Oncology Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Oncology Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 37. China Oncology Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 39. China Oncology Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Oncology Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Oncology Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Oncology Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Oncology Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Oncology Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Oncology Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 49. India Oncology Immunotherapy Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Oncology Immunotherapy Sales Value by Type (%), 2023 VS 2030
Figure 51. India Oncology Immunotherapy Sales Value by Application (%), 2023 VS 2030
Figure 52. Oncology Immunotherapy Industrial Chain
Figure 53. Oncology Immunotherapy Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation